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MOLECULAR DETERMINANTS OF SENSITIVITY TO POLY(ADP-RIBOSE) 
POLYMERASE INHIBITORS IN OVARIAN CANCER 
KEVIN O’CONNOR 
ABSTRACT 
Less than half of patients with epithelial ovarian cancer (EOC) survive five years 
following diagnosis, underscoring the imperative need for improved treatment. Many 
patients, including those with advanced disease, initially respond to platinum agents, 
which constitute the backbone of therapy. However, tumors ultimately become resistant, 
rendering further treatment ineffective. Additionally, the poor tolerability of these agents 
warrants the exploration of more targeted treatments – one such strategy is exploiting 
synthetic lethal genetic relationships. Recent genomic sequencing efforts have revealed 
that as many of half of EOCs have homologous recombination (HR) alterations. HR is a 
critical pathway for the repair of platinum-induced ICLs, thus compromised HR is 
hypothesized to explain the initial response to chemotherapy in many patients. 
Accordingly, women whose tumors harbor mutations in the critical HR genes, BRCA1 or 
BRCA2 (BRCA1/2), demonstrate improved prognosis. BRCA1/2 mutations also confer 
exquisite sensitivity to inhibitors of the enzyme, poly(ADP-ribose) polymerase 1 
(PARPis), hence loss of BRCA1/2 and PARP1 is synthetic lethal. A number of models 
have been proposed to explain this synthetic lethality, yet a consensus model that 
accounts for the diverse cellular roles of BRCA1/2 and PARP1 has yet to be established. 
Delineating the precise molecular underpinnings of PARPi action in BRCA1/2-deficient 
cells will aid clinicians in identifying the appropriate population of women with EOC 
  vii 
likely to benefit from PARPi treatment and provide insight into resistance mechanisms 
that arise in these patients. Combining this approach with retrospective analysis of PARPi 
clinical trials will best define the proper indication for PARPi in EOC and other human 
cancers. 
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INTRODUCTION 
 
1. Introduction to epithelial ovarian cancer 
Ovarian cancer was diagnosed in over 20,000 women in the U.S. alone in 2014, 
representing a considerable unmet healthcare need. Epithelial ovarian cancer (EOC) is the 
most common ovarian malignancy, comprising 85 to 90 percent of ovarian cancer 
diagnoses (National Ovarian Cancer Coalition (n.d.)). Lethality associated with this 
disease is reflected in the poor 5-year survival rate for EOC – a mere 44.6 percent 
(National Ovarian Cancer Coalition (n.d.)). Conventionally, surgical debulking followed 
by adjuvant (post-operative) platinum-based chemotherapy constitutes the standard of 
care for women with EOC. Although tumor regression is commonly observed with the 
first course of chemotherapy, resistance frequently develops, rendering additional 
treatment with cytotoxic agents ineffective (Jayson, Kohn, Kitchener, & Ledermann, 
2014). While platinum analogues have served as the backbone of EOC therapy for the 
past several decades, their associated toxicity and propensity for tumors to develop 
resistance, have driven researchers to explore safer and more effective alternatives 
(Jayson et al., 2014). 
 
While this review mostly aims to evaluate therapy related to high grade serous ovarian 
carcinoma (HGSOC), a disease genomically, histopathologically, and prognostically 
distinct from other ovarian cancer subtypes, a more inclusive overview of ovarian cancer 
epidemiology and histopathology can be found elsewhere (Jayson et al., 2014). As the 
majority of patients with EOC present with high grade serous histology, HGSOC and 
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EOC will be used interchangeably during this thesis. Additionally, since many tumors 
deficient in homologous recombination (HR)-mediated repair demonstrate loss-of-
function in BRCA1 or BRCA2, the terms “BRCA1/2-deficient” and “homologous 
recombination-deficient (HRD)” will also be used interchangeably for simplicity. 
 
Historically, patients with EOC have received a host of anti-neoplastic cytotoxic agents 
in the adjuvant setting, including cyclophosphamide, gemcitabine, cisplatin, carboplatin, 
doxorubucin, and paclitaxel (Markman, 2013). Standard of care has evolved to include 
adjuvant treatment with a combination of a platinum analog (typically carboplatin) and 
taxane (typically paclitaxel) (Jayson et al., 2014; Markman, 2013). Over the past two 
decades only modest changes have been made to this regimen. Namely, carboplatin has 
largely replaced cisplatin due to similar efficacy and superior tolerability, intraperitoneal 
(IP) administration of platinum has been shown to demonstrate improved efficacy over 
the intravenous (IV) route, and doclitaxel-carboplatin has been offered as an alternative 
to paclitaxel-carboplatin (with similar efficacy and different toxicity profiles) (Armstrong 
et al., 2006; Markman, 2013; Vasey et al., 2004).      
 
While many patients with EOC have favorable responses to platinum agents, a number of 
limitations, including severe toxicity and a plateau in efficacy, demand the exploration of 
alternative treatment strategies. One such strategy is the exploitation of synthetic lethality 
in EOC, which has been highlighted by the recent clinical application of poly(ADP-
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ribose) polymerase (PARP) inhibitors in cancers with mutations in homologous 
recombination (HR) genes, BRCA1 and BRCA2. 
 
2. Synthetic lethality in cancer 
Synthetic lethality is a term that refers to the condition where mutation in either one of 
two genes is compatible with cellular viability, but mutation in both genes leads to cell 
death (Hartwell, Szankasi, Roberts, Murray, & Friend, 1997; Kaelin, 2005) (Figure 1). 
This phenomenon was first used in describing cross-breeds of Drosophila pseudoobscura 
mutants (Dobzhansky, 1946) and has classically been utilized in order to uncover genetic 
interactions using screens in fly and budding yeast, Saccharomyces cerevisiae (Kaelin, 
2005; McLornan, List, & Mufti, 2014). S. cerevisiae was the first eukaryotic genome to 
be sequenced (Goffeau et al., 1996). Subsequently, a consortium of European and U.S. 
scientists generated nearly 7,000 mutant yeast strains with deletion in a single unique 
open reading frame (ORF) (referred herein as yeast knock out (YKO) strains), covering a 
significant fraction of the S. cerevisiae ORFs and showcasing the power of the yeast 
system as a tool to study gene function (Winzeler et al., 1999).  
 
Singly, 17% of mutations were lethal (representing genes essential for cell viability), 
consistent with a later study that generated YKO mutants covering 96% of annotated 
ORFs (Giaever et al., 2002). The remaining ~80% of genes represent candidate genes for 
investigating synthetic lethal genetic interactions using this yeast knockout platform. In 
fact, Tong and colleagues utilized synthetic genetic array (SGA) analysis in a 2004 study, 
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crossing >100 query genes (with critical functions related to cell polarity, cell wall 
synthesis, chromosome segregation, and DNA synthesis and repair) with ~4,700 YKO 
strains in order to identify such interactions (Tong et al., 2004). Their study uncovered an 
average of 34 synthetic lethal relationships per screen (while only 20% of screens failed 
to reveal a single synthetic lethal interaction for a given query gene).  
 
 
Figure 1. Model of synthetic lethality. In the context of normal cells, loss of Gene A or 
Gene B activity alone (left or middle) doesn’t compromise cell viability. In contrast, a 
tumor that has mutated Gene B is left vulnerable to therapeutic intervention inactivating 
Gene A (right), representing an opportunity for exploiting synthetic lethality between 
Gene A and Gene B. A therapy that targets Gene A would hypothetically spare normal 
cells, while selectively killing cancer cells. Adapted from (Rehman, Lord, & Ashworth, 
2010). 
 
Hartwell (1997) and later, Kaelin (2005), proposed that exploring synthetic lethal 
relationships in cancer cells may aid scientists in the discovery of selective anti-tumor 
agents (Hartwell et al., 1997; Kaelin, 2005). The 2005 finding that cancer cells deficient 
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in the breast cancer susceptibility genes BRCA1 and BRCA2 are exquisitely sensitive to 
inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP1) signified 
an exciting and relevant proof-of-concept for applying synthetic lethality to cancer 
therapy (Bryant et al., 2005; Farmer et al., 2005). Subsequently, this paradigm has gained 
tremendous momentum. Spurred by the Bryant et al. (2005) and Farmer et al. (2005) 
studies, and likely facilitated by enhanced and increasingly accessible genomic 
technology, there has been a surge over the past decade in publications that use synthetic 
lethality to explore new drug targets for cancer treatment (Figure 2). 
 
 
Figure 2. Publications on cancer synthetic lethality. Since 2005, there has been a 
striking increase in the number of publications using synthetic lethality to study cancer 
cells. Number of publications referenced in PubMed that match “Text Word” cancer and 
synthetic lethality was plotted for each year from 2000-2015. 
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The synthetic lethal approach to designing targeted cancer therapies is appealing for a 
number of reasons. First, exploiting synthetic lethality in cancer can lead to increased 
selectivity. Most cytotoxic chemotherapies exert their effects on rapidly dividing cells 
(i.e. cells that are actively undergoing DNA replication). Consequently, these drugs 
demonstrate toxicity to other highly replicative tissues like blood cell precursors in the 
bone marrow and gut mucosal cells (Kaelin, 2005). However, the toxicity of these agents 
is not necessarily limited to cells with a high proliferative index. Doxorubicin and 
bleomycin, which generate DNA double-strand breaks, also demonstrate toxicity to the 
heart and lung, respectively. Not surprisingly, these dose-limiting toxicities often 
compromise the effectiveness of these agents (Kaelin, 2005).   
 
Importantly, the application of synthetic lethality to cancer treatment utilizes a tumor’s 
context-dependent reliance on a specific molecular target. By mutating “Gene A” (or a 
biological pathway governed by Gene A) during the process of transformation, the cancer 
cells have acquired an Achilles heel of sorts (represented by “Gene B,” or the pathway 
governed by Gene B; Refer to Figure 1), leaving them vulnerable to attack. While 
healthy cells express the target of interest (Gene B), pharmacological inhibition of this 
target is buffered by the activity of Gene A (which is lost in cancer cells) (Kaelin, 2005). 
Under these conditions, the therapy would be selective to the tumor; enhancing cancer 
cell lethality, while largely leaving healthy tissue unscathed. 
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This approach also addresses a critical question that has long troubled translational cancer 
researchers – how do you target loss-of-function alterations in cancer cells therapeutically 
(i.e. mutations in tumor suppressor gene (TSG))? While tumor reliance on the loss of 
TSGs, including p53 (mutated in ~50% of all human cancers), has been demonstrated by 
in vitro and murine studies (Feldser et al., 2010), pharmacological or gene therapy-based 
reactivation of these genes has proven quite difficult (Hong et al., 2014; M. Lu et al., 
2014). Targeting compensatory proteins and/or pathways that become hyperactive in the 
setting of TSG loss averts this problem, offering an alternative strategy that takes 
advantage of a fundamental vulnerability of tumor cells.  
 
3. DNA repair genes as TSGs – an opportunity for synthetic lethal therapy 
Hanahan and Weinberg summarize the conventional hypothesis that illuminates why 
compromised DNA repair capacity may favor tumorigenesis (Hanahan & Weinberg, 
2011). They describe “hallmarks of cancer” as “acquired functional capabilities that 
allow cancer cells to survive, proliferate, and disseminate.” Importantly, a critical feature 
permitting these functional adaptations is the “development of genomic 
instability...which generates random mutations including chromosomal rearrangements; 
among these are the rare genetic changes that can orchestrate hallmark capabilities 
(Hanahan & Weinberg, 2011).”  Expressed differently, when DNA repair mechanisms, 
which serve to maintain genomic integrity, are inactivated, it may increase the pool of 
mutations from which tumors may gain a selective advantage. Stochastically, some of 
 8 
these mutations will favor transformation, tumor growth and maintenance, or metastasis, 
and thus confer survival benefit for pre-malignant or malignant cells.  
 
Homologous recombination (HR) is a major DNA repair pathway that serves to 
accurately repair DNA double-strand breaks (DSBs). BRCA1 and BRCA2 are two 
critical enzymes in HR. Predictably, loss-of-function germline mutations in these genes 
are highly penetrant and confer susceptibility to breast cancer, ovarian cancer, as well as 
other disorders (e.g. Fanconi anemia; Appendix 1) (Howlett et al., 2002; King, Marks, 
Mandell, & New York Breast Cancer Study Group, 2003; Moynahan, Chiu, Koller, & 
Jasin, 1999; Wooster et al., 1995). Women who inherit a mutant BRCA1 allele carry a 
lifetime ovarian and breast cancer risk of approximately 40% and 55-65%, respectively, 
while the corresponding risk for BRCA2 carriers is 45-50% and 11-18% (Antoniou et al., 
2003; Chen & Parmigiani, 2007). In concordance with Knudson’s two-hit hypothesis for 
TSGs, tumorigenesis in these women is frequently accompanied by loss of the wild type 
BRCA allele (Knudson, 1971; Welcsh & King, 2001).  
 
Consistent with Hanahan and Weinberg’s suggestion, genomic sequencing has revealed 
that BRCA1- and BRCA2-deficient tumors demonstrate an elevated incidence of non-
synonymous somatic mutations, perhaps owing to lower fidelity compensatory pathways 
that are hyperactive in the absence of HR (Ceccaldi, Liu, et al., 2015; J. Lu, Wu, Li, 
Zhou, & Hao, 2014; T. C. G. A. R. Network, 2011). Furthermore, BRCA1/2-deficient 
tumors (e.g. a fraction of breast, ovarian, and pancreatic cancers) were found to have a 
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mutational signature consistent with the utilization of lower fidelity repair processes in 
the absence of HR (Alexandrov et al., 2013). Importantly, this paradigm reflects a 
“double-edged sword” for patients with mutations in BRCA genes. While these 
alterations favor tumor formation, they also represent potentially appealing directed 
therapeutic opportunities (e.g. inhibition of PARP1). Moreover, it has been demonstrated 
that EOC patients with cancers harboring BRCA1 or BRCA2 mutations show enhanced 
platinum response that often translates to improved survival (T. C. G. A. R. Network, 
2011; Tan et al., 2008) (Figure 3).  
 
Figure  3. Ovarian cancer patients with BRCA-mutated tumors demonstrate 
improved survival. Kaplan-Meier plot generated using cBioportal for patients from 
Ovarian serous cystadenocarcinoma TCGA study (T. C. G. A. R. Network, 2011). P-
value calculated using Logrank test.   
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4a. DNA repair mitigates response to chemotherapeutic agents 
DNA repair is a critical boundary to tumorigenesis and is required for cell survival. 
Under normal conditions, human cells encounter approximately 10
5
 DNA lesions per day 
as a product of normal cellular processes and an additional 10
5
 from exposure to 
environmental agents (e.g. ionizing radiation (IR) or ultraviolet (UV) light) (Ciccia & 
Elledge, 2010). The threat posed by these ubiquitous lesions is mitigated by a complex 
and diverse network of DNA repair mechanisms that have evolved to tolerate genotoxic 
stress. These mechanisms are especially pertinent in the repair of chemotherapy-induced 
damage, as the majority of cancer chemotherapeutics used today exert their effect by 
either damaging DNA directly (e.g. alkylators, intercalators, etc.) or altering DNA 
metabolism (e.g. methotrexate). Importantly, tumors that have inactivated the DNA repair 
machinery in the process of malignant transformation frequently demonstrate enhanced 
response to genotoxins (Kennedy & D’Andrea, 2006).  
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Figure 4. Mechanism of action and associated toxicities for first-line EOC therapies. 
A) Chemical structures of cisplatin and carboplatin. Carboplatin has a bulkier, 
cyclobutane-containing leaving group, lending to an enhanced safety profile. Mechanism 
for cisplatin (CDDP)-DNA binding shown.  CDDP can generate covalently linkages 
between adjacent purine bases (left, ~90% of CDDP-DNA adducts), or between purines 
on opposing DNA strands (right, ~10% of CDDP-DNA adducts). Recognition of CDDP-
DNA lesions leads to cell cycle arrest and either proper DNA repair or apoptosis. B) 
Chemical structures for paclitaxel and docetaxel are shown. Both compounds exert their 
effect by binding β-tubulin, and stabilizing microtubules, leading to prolonged cell cycle 
arrest and apoptosis. Figure adapted from (Kelland, 2007; Montero, Fossella, Hortobagyi, 
& Valero, 2005). 
 
Platinum analogs exert their toxicity by generating covalent linkages between either 
adjacent deoxyribonucleotide bases (“intrastrand crosslinks”) or between bases on 
complementary DNA strands (“interstrand crosslinks”) (Figure 4). Activated platinum 
molecules bind to the N7 position on the imidazole ring of (mostly) guanine bases  
(Kelland, 2007). By spanning the DNA double helix, platinum crosslinks impede a 
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number of vital cellular processes, including transcription and replication (Deans & West, 
2011; Moldovan & D’Andrea, 2009). While the majority of platinum-DNA adducts 
generated by these agents are intrastrand crosslinks between purine bases (Kelland, 
2007), interstrand crosslinks (ICLs) represent especially harmful lesions, as their repair 
requires a complex molecular machinery and the transient generation of a DSB (Kim & 
D’Andrea, 2012). Moreover, unresolved ICLs prevent the unwinding of duplex DNA, 
leading to DNA breaks and chromosomal rearrangements (Deans & West, 2011). For 
these reasons, capacity to repair ICLs is considered a major factor in platinum 
cytotoxicity (Chirnomas et al., 2006; Deans & West, 2011; Jacquemont, Simon, 
D’Andrea, & Taniguchi, 2012; Kennedy & D’Andrea, 2006; Taniguchi et al., 2003).  
 
4b. HR deficiency and sensitivity to ICL-creating drugs 
ICLs are repaired by the Fanconi anemia (FA) pathway – an intricate signaling and repair 
network that employs factors involved in DNA Damage Response (DDR) signaling (e.g. 
ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia and Rad3-related (ATR) 
kinases), nucleotide excision repair (NER), translesion synthesis (TLS), and HR (see 
below) pathways. This tightly regulated network collaborates in the recognition, excision, 
and repair of ICLs encountered during DNA replication (Figure 5). More recently, the 
ICL repair pathway has been referred to collectively as the “FA/BRCA pathway,” in 
deference to the downstream requirement of the HR enzymes BRCA1 and BRCA2.     
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Figure 5. Interstrand crosslink repair. ICL repair can be considered in several linear 
steps: 1) convergence of bi-directional replication forks and lesion recognition, 2) 
nucleolytic incision by FANCD2/I-recruited nucleases and lesion bypass (TLS= 
translesion synthesis), and 3) repair by homologous recombination. Figure amended from 
(Ceccaldi, Sarangi, & D’Andrea, 2016). 
 
The three basic steps of ICL repair are: 1) recognition, 2) incision, and 3) HR-mediated 
DSB repair. Crosslink recognition is accomplished by the FA core complex, a ubiquitin 
ligase, which senses the lesion and propagates downstream signaling to other repair 
factors. Incision is achieved by a host of nucleases, which are recruited by the activated 
(ubiquitinated) heterodimeric scaffold FANCD2-FANCI, and catalyze unhooking of the 
DNA crosslink (Ceccaldi, Sarangi, et al., 2016). This processing generates a DSB 
opposite the unhooked ICL. While low-fidelity TLS polymerases are able to insert a 
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nucleotide across from the unhooked DNA-ICL adduct and extend the nascent DNA 
strand, the opposing DSB is repaired by downstream HR factors, thus completing faithful 
resolution of the ICL (Ceccaldi, Sarangi, et al., 2016). Due to the requirement of HR 
proteins for proper completion of ICL repair, disruption of HR genes (such as BRCA1 
and BRCA2) results in enhanced cellular sensitivity to ICL-inducing agents, like 
platinum. 
 
4c. ICL repair-independent roles of HR: DSBs and replication fork integrity 
i. Function of Homologous Recombination in DSB repair  
As discussed, DSBs are generated deliberately during the normal resolution of ICLs and 
require the HR machinery for appropriate repair. HR has a multitude of functions 
independent of ICL repair however, including replication fork stabilization and the 
resolution of DSBs that occur from other sources. DSBs can arise from exogenous 
sources of damage (e.g. IR) or from perturbations of normally occurring cellular 
processes (e.g. reactive oxygen species, collapsed replication forks or dysfunctional 
telomere maintenance) (Khanna & Jackson, 2001; Lieber, 2010). Its fidelity hinges upon 
the availability of a homologous repair template, provided by the sister chromatid during 
S- and G2-phase. While HR is largely considered an error-free repair mechanism, its 
activity is tightly controlled by a number of regulators to ensure it is used only in the 
proper cellular context (Orthwein et al., 2015) (Figure 6). The multiple levels of 
regulation prevent genetic events like translocations (from HR between non-allelic 
sequences) or loss of heterozygosity (LOH; from HR between homologs), which may 
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favor tumor formation (Luo et al., 2000; Moldovan et al., 2012; Moynahan & Jasin, 
1997; Richardson, Moynahan, & Jasin, 1998).  
 
Figure 6. HR repair and its regulation. In response to a DSB, end resection by CtIP 
and the MRN complex reveals DNA overhang structures compatible with RAD51 
nucleofilament formation and HR repair (Left). Not shown is resolution of displacement 
loop (D-loop) structures. Negative regulators of HR at distinct steps may favor error-
prone repair pathways (Right). CO=cross over. SDSA=synthesis dependent strand 
annealing. Taken from (Ceccaldi, Rondinelli, & D’Andrea, 2016). 
 
BRCA1 functions in two critical steps in HR. First, by binding CtIP and antagonizing the 
resection anatagonist 53BP1, it promotes generation of 3’ ssDNA overhangs that serve as 
HR substrates. Second, through its interaction with PALB2 (partner and colocalizer of 
BRCA2), BRCA1 recruits BRCA2 to the DSB, allowing RAD51 loading (Prakash, 
Zhang, Feng, & Jasin, 2015). The recombinase RAD51 is loaded onto DNA to form 
RAD51-DNA nucleofilaments, displacing replication protein A (RPA) (which binds and 
protects ssDNA after the generation of early HR intermediates) in a BRCA1-, BRCA2-, 
and PALB2-dependent fashion. BRCA2 is thought to inhibit the intrinsic ATPase activity 
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of RAD51, thus stabilizing RAD51-ATP bound to ssDNA. This complex is able to 
promote recombination by catalyzing the strand invasion step of HR (Prakash et al., 
2015). Since HR utilizes a homologous template for repair, this process generally leads to 
error-free DSB resolution and the preservation of genomic integrity. Consequently, as 
discussed previously, HR is a vital to preventing mutations that may favor tumorigenesis 
and many of the genes involved in promoting HR (i.e. BRCA1, BRCA2, PALB2, etc.) 
are bona fide TSGs.  
ii. Function of HR genes in fork stability 
In addition to repairing DSBs that arise from collapsed replication forks, BRCA1 and 
BRCA2 were also recently attributed a role in protecting stalled forks from nucleolytic 
degradation via a RAD51-dependent mechanism  (Hashimoto, Ray Chaudhuri, Lopes, & 
Costanzo, 2010; Schlacher et al., 2011; Schlacher, Wu, & Jasin, 2012). As previously 
mentioned, stalled replication forks can lead to collapse and genomic instability from 
DSBs. FA proteins, including FANCD2 also localize to and similarly protect the integrity 
of stalled replication forks (Lossaint et al., 2013; Schlacher et al., 2012).  
 
iii. Consequences of HR deficiency 
1. Hyperdependence on alternative DSB repair pathways (NHEJ, alt-EJ, SSA) 
Cells deficient in HR repair rely on the activity of alternative repair pathways for 
survival. In order to appropriately resolve DSBs and maintain genomic stability in normal 
(i.e. HR-proficient) cells, there is a delicate balance between the activity of competing 
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repair processes. DSBs are predominantly resolved by one of two DNA repair 
mechanisms: non homologous end joining (NHEJ) or HR. NHEJ is a high-kinetic, 
versatile, and relatively error-prone mechanism that orchestrates the ligation of two blunt 
DNA ends, without the requirement for sequence homology. NHEJ activity is cell-cycle 
regulated, typically restricted to G0/G1 cells (Ceccaldi, Rondinelli, et al., 2016). HR, on 
the other hand, is the preferred DSB repair pathway for actively replicating cells and for 
the resolution of DSBs generated during ICL processing. DSB repair pathway choice is 
largely determined by accessibility of DNA ends. Whereas Ku70/80 binding of DNA 
ends favors NHEJ, DNA end resection effectively commits the cell toward homology-
directed mechanisms (HR, single-strand annealing (SSA), and alternative end joining 
(alt-EJ)) (Ceccaldi, Rondinelli, et al., 2016; Fell & Schild-Poulter, 2015; Lieber, 2010).  
 
An initial “end clipping” of DNA ends is catalyzed by the structure-specific nucleases 
MRE11 and CtIP (Sartori et al., 2007; You et al., 2009), followed by more extensive end 
resection involving a number of nucleases and helicases (Ceccaldi, Rondinelli, et al., 
2016). Resection at DSBs in the 5’ to 3’ direction generates 3’ single strand DNA 
(ssDNA) overhangs. These stretches of ssDNA are rapidly coated and protected from 
forming secondary structures by replication protein A (RPA). In order to promote the 
predominant homology-dependent process, HR, RAD51 is then loaded onto ssDNA, 
displacing RPA and catalyzing homology search and strand invasion (Kim & D’Andrea, 
2012).  
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Two other homology-dependent processes, single-strand annealing (SSA) and alternative 
end joining (alt-EJ) also contribute to the cellular DSB repair machinery (Ceccaldi, 
Rondinelli, et al., 2016). While historically considered a “back-up” pathway, alt-EJ was 
recently ascribed a critical role in the viability of cancer cells deficient in HR repair 
(Ceccaldi, Liu, et al., 2015; Mateos-Gomez et al., 2015).  
 
As expected, tumors that inactivate HR during transformation rely to a great extent on the 
activity of compensatory repair pathways like NHEJ and alt-EJ to maintain a state of 
genomic stability compatible with viability (Kennedy & D’Andrea, 2006). These 
hyperactive compensatory pathways often constitute synthetic lethal relationships, thus 
lending to potential therapeutic targets. Consistent with this model, HR-deficient (HRD) 
tumors rely on PARP1-catalyzed repair processes (Bryant et al., 2005; Farmer et al., 
2005; McCabe et al., 2006). PARP1 is a versatile enzyme involved in a number of critical 
cellular processes (Figure 8), yet early studies of HR/PARP1 synthetic lethality mostly 
credited PARP1-mediated base excision repair (BER; see below) as the vital repair 
pathway underlying this relationship (Bryant et al., 2005; Farmer et al., 2005). The 
contribution of PARP1’s role to these different processes will be discussed later in detail.  
 
PARP1 has also been ascribed a role in replication fork protection, which may be 
especially critical in HRD cells. PARP1 (in conjunction with PARP2) recruits MRE11 to 
replication forks stalled with either hydroxyurea (HU; a ribonucleotide reductase 
inhibitor) or double thymidine block (which impedes replication by depleting dCTPs), 
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promoting resection and HR-mediated fork restart (Bryant et al., 2009). While MRE11 is 
required for the restart of stalled forks, in the setting of BRCA2 deficiency, excessive 
MRE11-dependent degradation can compromise fork integrity. Interestingly, in this 
context PARP1 plays a critical role in protecting forks from excessive nucleolytic 
processing (Ying, Hamdy, & Helleday, 2012). Further molecular studies revealed that 
PARP1 and DNA-PK are required for recruitment of XRCC1 in order to protect stalled 
replication forks from resection and promote efficient repair and restart (Ying et al., 
2015). Exploring the role of PARP1 in HRD cells with respect to DNA repair pathway 
choice and replication fork integrity may shed light on the mechanism of synthetic 
lethality. While it seems clear that PARP1 activity is upregulated when HR is lost, further 
study is needed to clarify which PARP1 functions are required for the viability of HRD 
cells. 
 
4d. Somatic inactivation of the FA/BRCA pathway in EOC and TNBC 
In 2011, whole genome sequencing of 316 HGSOCs revealed several hallmark genetic 
features of ovarian cancer, including alterations in the FA/BRCA pathway (T. C. G. A. R. 
Network, 2011). Consistent with the high level of genomic instability in this disease, p53 
mutations were found in nearly every sequenced tumor (96%). Other statistically 
significantly mutated genes were NF1, RB1, BRCA1, BRCA2, and CDK12. Remarkably, 
gene ontology analysis revealed that roughly half of EOCs harbor alterations in HR repair 
(Figure 7), including BRCA1/2 germline/somatic mutations (21%), BRCA1 epigenetic 
silencing (11%),  EMSY amplification or mutation (8%), focal deletion of PTEN (7%), 
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hypermethylation of RAD51C (3%), mutation of ATR/ATM (2%), and somatic 
mutations in FA genes (5%) (T. C. G. A. R. Network, 2011).  
 
An earlier study also published by The Cancer Genome Atlas Network (TCGA) that 
sequenced nearly 500 breast carcinomas, revealed roughly 20% of basal like breast 
cancers demonstrated germline or somatic mutations in BRCA1 or BRCA2 (T. C. G. A. 
Network, 2012). Moreover, copy number and gene expression analysis revealed that 
these tumors were genomically similar to EOC, forwarding the compelling hypothesis 
that HRD cancers may be more similar across anatomical origin than HR proficient 
tumors arising from the same primary site.  
 
 
Figure 7. Genetic and epigenetic landscape of FA/BRCA/HR alterations in HGSOC. 
154 out of the 316 (49%) sequenced HGSOC tumors harboring FA/BRCA alterations are 
shown. Each column represents an individual tumor. Orange indicates heterozygous loss 
(loss of the accompanying wild type allele). Figure taken from (T. C. G. A. R. Network, 
2011). 
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5. Poly (ADP-ribose) polymerase 1 (PARP1) and DNA repair 
PARP1 is a versatile enzyme that functions in numerous cellular processes, including the 
sensing and resolution of DNA strand breaks (Figure 8). Its most well-defined role in 
mammalian cells is the catalysis of base excision repair (BER), a pathway that excises 
damaged nucleotides, including oxidative damage, abasic sites, and the presence of uracil 
residues in DNA strands (Dantzer et al., 2000; De Lorenzo, Patel, Hurley, & Kaufmann, 
2013). In response to genotoxic damage, PARP1 is activated, recruited to chromatin, and 
subsequently catalyzes the transfer of poly(ADP-ribose) (PAR) moieties from NAD
+
 to 
repair factors, enhancing their recruitment to damage sites. Perhaps most critical in BER 
is PARP1’s role in bringing scaffolding protein x-ray cross complementing protein 1 
(XRCC1) to damaged bases. XRCC1, in turn, serves as a docking site for the binding of 
additional BER factors, which catalyze the excision of the damaged base and restore 
genomic stability (Figure 8) (De Lorenzo et al., 2013). 
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Figure 8. Biological functions of PARP1. A) PARP1 has a number of functional 
domains that bestow it with versatile cellular functions. Residues notated with an asterisk 
are critical for Nicotinamide adenine dinucleotide (NAD
+
) binding (Histidine, Tyrosine) 
and polymerase activity (Glutamate). DBD=DNA binding domain. AD=automodification 
domain B) PARP1 serves as a sensor of DNA damage. Upon detection of a DNA strand 
break, PARP1, using NAD
+
 as a cofactor,  catalyzes the production of poly ADP-ribose, 
which is conjugated to acceptor proteins and itself, either covalently or non-covalently 
(This activity is counteracted by poly(ADP-ribose) glycohydrolase (PARG); modified 
proteins are shown in blue boxes). The effect of these modifications is briefly described. 
SSB=single strand break; DNA-PKcs=DNA-protein kinase catalytic subunit; 
DSB=double strand break; NHEJ= non homologous end joining; HR=homologous 
recombination; ATM=ataxia telangiectasia mutated. Figure amended from (Rouleau, 
Patel, Hendzel, Kaufmann, & Poirier, 2010). 
 
6.  Development of PARP inhibitors for cancer therapy 
The observation that cells deficient in homologous recombination (HR) are exquisitely 
sensitive to inhibition of PARP1 has forwarded the hypothesis that there is a synthetic 
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lethal relationship between the two repair pathways (i.e. HR and PARP1-catalyzed BER) 
(Bryant et al., 2005; Farmer et al., 2005). Subsequent research has ultimately led to the 
development of selective and potent inhibitors of PARP1 (Table 1) (Liu, 
Konstantinopoulos, & Matulonis, 2014). In December 2014, the PARP inhibitor (PARPi) 
olaparib was approved for the treatment of germline-BRCA1 and -BRCA2 mutated 
ovarian cancers (“Lynparza New FDA Drug Approval | CenterWatch,” n.d.). While 
PARPi show promise as a selective therapy for EOC (and other solid tumors), there has 
been much debate over their mechanism of selectivity for HR-deficient cells.  Elucidation 
of the mechanism is a considerable obstacle to determining the proper population of 
patients likely to benefit from PARPi treatment. Furthermore, uncovering the molecular 
mechanism of PARPi activity will shed light on potential resistance mechanisms that may 
arise in patients whose tumors initially respond to PARPi therapy. 
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Specific Aims and Objectives 
The mechanism by which PARP inhibitors are “synthetically lethal” in a subset of tumors 
is a topic of much debate. Since the initial observation of the synthetic lethal 
phenomenon of PARPi treatment in BRCA1- and BRCA2-deficient cells (Bryant et al., 
2005; Farmer et al., 2005), there have been several models proposed for the mechanism 
that explains the underlying sensitivity of these cells (De Lorenzo et al., 2013; 
Konstantinopoulos, Ceccaldi, Shapiro, & D’Andrea, 2015). Moreover, recent genomic 
studies revealed other HR or HR-like alterations in EOC that may confer clinical 
response to PARPi  (Gelmon et al., 2011; Lord, Tutt, & Ashworth, 2015; T. C. G. A. R. 
Network, 2011). Expounding on the putative mechanism proposed for PARPi response in 
EOC and evaluating factors proposed to govern PARPi sensitivity will provide critical 
insight into these pressing questions.  
The specific aims of this study are: 
1. Summarize rationale for targeting PARP in EOC and outline future directions 
for the utilization of PARPi therapy in this disease 
2. Appraise proposed mechanisms of synthetic lethality between BRCA1/2-
deficient tumors and PARPi treatment and present a comprehensive model 
3. Provide perspective for why understanding the biological mechanisms 
underpinning synthetic lethality can better define EOC patients who may 
respond well to PARPis 
I hope to leverage genomic and genetic information from whole exome and whole 
genome sequencing studies of EOC, as well basic science literature on DNA repair 
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pathway choice and PARP activity in the context of HR deficiency in order to shed light 
on the in vivo mechanism of PARPi action in EOC. Moreover, this study aims to 
demonstrate how this information may inform further investigation into predictors of 
tumor response to PARPis. 
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`PUBLISHED STUDIES 
 
1a. Early development of PARP inhibitors 
PARP inhibitors (PARPi) were initially developed to potentiate the activity of anti-tumor 
genotoxins. By using chemotherapeutic agents that directly damage DNA and 
concurrently inhibiting the repair of that damage (with the use of PARPi), investigators 
hoped to improve the efficacy of these drugs. In fact, pre-clinical evaluation of early 
PARPi revealed a potent radiosensitization effect (Calabrese et al., 2004), as well as 
enhanced sensitivity to chemotherapeutics like temozolomide (a DNA alkylating agent), 
topotecan and ironotecan (Topoisomerase poisons), and cisplatin (Calabrese et al., 2004; 
Miknyoczki et al., 2003; Tentori et al., 2003). While met with early promise, a major 
limitation of the combined approach (i.e. chemotherapy plus PARPi) was the overlapping 
myelosuppression of the two agents (Liu et al., 2014). Moreover, the 2005 finding that 
BRCA-deficient cells are selectively and exquisitely sensitive to PARPi supplied the 
motivation for evaluating the potential of PARPis as a monotherapy for BRCA1/2-
deficient tumors (Bryant et al., 2005; Farmer et al., 2005).  
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Table 1. Current status of PARP inhibitors under clinical investigation. List of 
PARPis in clinical trials for ovarian cancer. PO=Oral administration  *Note: Olaparib 
received FDA approval December 2014. Table adapted from (Liu et al., 2014). 
Additional information from (“Home - ClinicalTrials.gov,” n.d.). 
 
PARP Inhibitor Route EOC Studies Ongoing or 
Completed 
Olaparib (AZD2281) PO Phase I, II, and III* 
Veliparib (ABT-888) PO Phase I, I, and III 
Niraparib (MK4827) PO Phase I, II, and III 
Rucaparib (CO338, AGO14699 and 
PF01367338 
PO Phase I, II, and III 
Talazoparib (BMN673) PO Phase I and II 
 
Generally PARPis are small molecules that mimic the cofactor NAD
+
 and thus compete 
for the enzyme’s active site (Ratnam & Low, 2007). A list of PARPis currently under 
clinical investigation for EOC is presented in Table 1. Importantly, PARPis also inhibit 
PARP2, an enzyme in the same family, which is also involved in DNA repair and has 
been shown in murine knockout studies to compensate for the loss of PARP1 (Ménissier 
de Murcia et al., 2003).  
 
1b. Clinical investigation of PARPi in EOC 
While platinum analogs have long served as the backbone of EOC, the challenges 
presented by their toxicity and tumor resistance necessitate the investigation of improved, 
targeted treatments that can effectively exploit tumor-specific genetic features. A 
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hallmark example of this transition from conventional chemotherapeutics to a targeted 
agent (with a markedly better therapeutic window) is the development of Gleevec 
(imatinib), an inhibitor of the constitutively active ABL kinase, which results from the 
9:22 reciprocal chromosomal translocation (Philadelphia chromosome) underlying 
chronic myeloid leukemia (CML) (Druker et al., 2001). A recent review by 
Konstantinopoulos et al. (2015) poignantly describes homologous recombination 
deficiency (a feature of roughly 50 percent of HGSOCs) as “the fundamental 
vulnerability of ovarian cancer” (Cancer Genome Atlas Research Network, 2011; 
Konstantinopoulos et al., 2015). Similar to the BCR-ABL fusion kinase in CML, HR 
deficiency presents an appealing avenue for therapeutic intervention. Specifically, cancer 
cells harboring mutations in BRCA1/2 demonstrate enhanced response to PARPis 
(Bryant et al., 2005; Farmer et al., 2005). Notably, patients who inherit germline variants 
of BRCA1/2 frequently demonstrate loss of the wildtype allele (i.e. via LOH); the 
consequence is tumor-specific loss of HR activity (while other tissues retain the normal 
allele and are thus HR proficient) (Welcsh & King, 2001). Moreover, tumors without 
bona fide BRCA1/2 mutations may also have underlying HR deficiencies (a phenomenon 
referred to as “BRCAness” (Konstantinopoulos et al., 2010; Turner, Tutt, & Ashworth, 
2004)), and thus may similarly respond to PARPis. 
 
Prompted by the discovery of this synthetic lethal interaction, a number of clinical trials 
were launched to explore PARPi treatment for BRCA1/2 mutant tumors. The first phase I 
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trial evaluated olaparib in a small group of breast, ovarian or prostate cancer patients, 
enriched for patients with confirmed germline BRCA1/2 mutations (Fong et al., 2009). In 
this study olaparib demonstrated favorable pharmacokinetic parameters, effectively 
inhibited PARP in tumor samples, and was relatively well-tolerated even at maximum 
tolerated dose (MTD), compared to standard-of-care chemotherapy (Fong et al., 2009; 
Lord et al., 2015). Durable tumor responses (partial or complete) in this trial were limited 
to BRCA1/2 carriers, validating the enhanced effectiveness of PARPis in this context. As 
a result of these findings, the study was expanded to a subsequent cohort of 50 patients 
with ovarian, fallopian tube, or peritoneal cancer with germline BRCA1/2 mutations 
(Fong et al., 2010). In this expansion study, 40% of patients achieved Response 
Evaluation Criteria In Solid Tumors (RECIST) partial or complete responses, and/or 
decreases in EOC-associated tumor marker CA125 levels. The authors also observed a 
significant correlation between favorable clinical response to olaparib and prior platinum 
sensitivity. 
 
Though many of these patients achieved durable responses to olaparib, they ultimately 
developed resistance, highlighting the vital need to understand molecular mechanisms 
implicated in PARPi response. It might have been expected that due to the requirement of 
BRCA1/2 in the repair of both platinum-induced lesions (i.e. ICLs) and PARPis, that 
olaparib-resistant tumors would be refractory to additional platinum therapy. 
Surprisingly, retrospective analysis revealed that many of the patients who acquired 
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olaparib resistance still demonstrated clinical response to subsequent platinum treatment, 
suggesting resistance mechanisms for PARPi and platinum are not always shared (Ang et 
al., 2013). Consistent with these data, we found that alterations in the nucleotide excision 
repair (NER) pathway (a critical repair pathway for the resolution of intrastrand 
crosslinks), which occur in a subset of EOC patients (~8%), confer sensitivity to 
cisplatin, but not PARPi (Ceccaldi, O’Connor, et al., 2015). Thus future investigation is 
required to uncover which tumor-associated mutations will confer sensitivity to these 
agents.   
 
While recent clinical investigation has confirmed that BRCA1/2-mutant patients show 
favorable responses to olaparib, leading to its eventual approval for this indication (i.e. 
patients with germline BRCA1/2 mutations who have undergone at least three prior 
rounds of chemotherapy) (Audeh et al., 2010; Fong et al., 2009, 2010; Gelmon et al., 
2011; Kaye et al., 2012), there are several major issues that remain unresolved.  In a trial 
that evaluated patients with high grade ovarian carcinoma (intended to enrich for patients 
with BRCA1/2-mutated tumors), positive clinical responses were observed in a subset of 
non-BRCA-mutated patients, suggesting that other factors may also confer PARPi 
sensitivity (Gelmon et al., 2011). A detailed understanding of why PARPis are especially 
effective in the setting of BRCA1/2 loss may hint at alternative factors that would predict 
PARPi response. 
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Another major limitation of PARPi treatment is the acquisition of resistance. One 
strategy that may be effective in addressing resistance is the development of more potent 
PARPis for EOC. In fact, there are several PARPis at advanced stages of clinical 
development for ovarian cancer and other solid tumors where BRCA1/2 mutations are 
frequently observed (Table 1). Another strategy is the use of preclinical models to predict 
and then validate mechanisms underlying PARPi resistance (see below). A fine-scale 
understanding of BRCA1/2-PARPi synthetic lethality will aid tremendously in these 
efforts. Finally, a careful evaluation of olaparib’s current indication (for patients with 
germline BRCA1/2-mutated tumors, who have had at least three prior rounds of 
chemotherapy) is required. While this subset of patients have benefitted from PARPi 
treatment, the narrow indication may explain why this therapy hasn’t translated into 
improved survival and may exclude women who may also stand to benefit from PARPi. 
Considering BRCA-deficient tumors often become cross-resistant to platinum agents and 
PARPi, it may be more effective to employ PARPi as a front-line agent in EOC, prior to 
platinum exposure and subsequent development of resistance. It seems more likely, 
however, that for at least in the foreseeable future PARPis will be employed as 
maintenance monotherapy for recurrent HGSOC (in BRCA1/2-mutant cancers). Of note, 
there are a number of ongoing clinical trials that aim to evaluate PARPis in combination 
with other targeted therapies that have been met with success in EOC and other cancers 
(Appendix II). As some of these targeted agents are hypothesized to inhibit HR by 
various mechanisms, these combinations may be able to extend both the effectiveness 
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and range of PARPi for ovarian cancer therapy (i.e. BRCA-proficient patients may also 
benefit) (Konstantinopoulos et al., 2015). 
 
2. Proposed mechanisms of BRCA1/2-PARPi synthetic lethality 
Catalytic inhibition of PARP1/2 was hypothesized to selectively kill BRCA-deficient 
cells by preventing the repair of spontaneous DNA single-strand breaks (SSBs), which 
stall and subsequently collapse replication forks (Bryant et al., 2005; Farmer et al., 2005). 
Ultimately these lesions lead to DSBs that are particularly lethal in cells with 
compromised HR (Figure 9A). Recent evidence has challenged this model and more 
refined mechanisms have been proposed to explain the synthetic lethal relationship. 
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Figure 9. Proposed mechanisms for HR/PARPi synthetic lethality. A) PARPi inhibits 
PARP1-mediated BER, thus enabling SSBs to be converted into DSBs, which cannot be 
properly repaired in HR defective cells B) NHEJ activity is toxic to HR-deficient cells. 
Normally, NHEJ is restricted by PARP1. Upon PARPi treatment, toxic NHEJ leads to 
error prone repair and genomic instability C) PARPi traps PARP1 at sites of DNA 
damage, inhibiting PARP1-mediated recruitment of repair factors and generating 
complexes that impede DNA replication D) PARP1-catalyzed PARylation is required for 
BARD1-dependent recruitment of BRCA1 to DNA damage sites. PARPi prevents proper 
BRCA1 recruitment E) Alt-EJ is upregulated to catalyze DSB repair in the absence HR. 
PARPi inhibits this compensatory mechanism, thus cells are unable to repair DSBs. F) 
BRCA2 and PARP1 act in parallel pathways to protect stalled replication forks from 
collapse. When BRCA2-deficient cells are treated with PARPi, cells are unprotected 
from excessive nucleolytic degradation. Amended from (Konstantinopoulos et al., 2015; 
Ying et al., 2012). 
 
 34 
i. Catalytic inhibition of PARP1/BER 
Various components of PARP1/2 biology have been invoked to explain the synthetic 
lethal relationship between HR and PARPi, yet a sufficient and universally accepted 
model remains elusive. The canonical model proposed that spontaneously-arising SSBs 
left unrepaired by PARPi are converted to DSBs that are cell-lethal in the setting of an 
HR defect (Figure 9A) (Bryant et al., 2009; Farmer et al., 2005). While this mechanism 
credits PARP1’s most well-characterized role in DNA repair, a number of recent studies 
highlight its limitations. Namely, BRCA1/2-deficient cells are largely unaffected by 
depletion of the downstream BER effector, XRCC1 (Patel, Sarkaria, & Kaufmann, 2011). 
Furthermore, Murai et al. (2012) demonstrated that the PARPi olaparib, administered at 
“PARP trapping doses” sensitized more to the alkylating agent MMS (which generates 
substrates for BER) than PARP1 knockout, thus suggesting PARP-DNA complexes 
(rather than simply inhibition or loss of PARP1 activity) are critical for PARPi 
cytotoxicity.  
 
ii. PARP1 regulation of NHEJ 
NHEJ is a relatively error-prone pathway that may drive genomic instability when 
dysregulated by favoring the loss of genetic information (deletions), or chromosomal 
rearrangements (translocations) (Lieber, 2010). A link between PARP1 and NHEJ was 
supported by the observation that many NHEJ factors, including DNA-PK and Ku80, 
bind to PAR polymers (Gagné et al., 2008). In fact, PARP1 appears to be a negative 
 35 
regulator of NHEJ, potentially by competing with Ku80 for DNA ends (Hochegger et al., 
2006; Saberi et al., 2007; Wang et al., 2006). In the setting of HR loss, NHEJ activity 
may be especially detrimental to cells, potentially explaining the chromosomal instability 
(Appendix I) observed in cells deficient in the FA/BRCA pathway (Adamo et al., 2010; 
Pace et al., 2010). PARPi exposure was shown to promote NHEJ in HRD cells (as 
measured by increased phosphorylation of DNA-PKcs and an NHEJ reporter assay) and, 
importantly, the accompanying genomic instability (mutation frequency, chromosomal 
aberrations, and γH2AX foci formation (a measure of elevated DSB), as well as PARPi 
sensitivity, were suppressed by pharmacological inhibition of DNA-PK or depletion of 
Ku80 (Patel et al., 2011). Consistent with this model of an HR/NHEJ balance, we 
recently demonstrated that the growth defect of HRD FA cells can be rescued by 
inhibition of NHEJ activity (Zhang et al., 2016). Thus, if PARP1 normally suppresses the 
toxic effects of NHEJ in HRD cells, it’s feasible that PARPi treatment may drive lethality 
by promoting excessive NHEJ-mediated genomic instability (Figure 9B).  
 
iii. Toxicity of PARP-DNA complexes in HRD cells 
PARPis, to varying degrees, possess the ability to trap PARP1 and PARP2 at sites of 
DNA damage, forming complexes that impede the replication fork (Murai et al., 2012). 
Auto-poly(ADP)-ribosylation (auto-PARylation) of PARP1 is required for its release 
from site of DNA damage. Murai et al. proposed that in addition to preventing this 
release by catalytic inhibition of PARP, PARPi binding at the active site allosterically 
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enhances the binding of PARP’s zinc finger domain. Consistent with the former 
hypothesis, PARP-DNA binding is comparably enhanced by either treating with 
BMN673 (Talazoparib) or depleting NAD
+
, both of which inhibit auto-PARylation 
(Murai et al., 2012). Contrary to the allosteric inhibition hypothesis, crystal structure of a 
PARP1-PARPi complex revealed that PARPi binding was restricted to the active site. 
This binding was accompanied by merely subtle conformational changes, unlikely to 
affect PARP1’s DNA binding domain (Murai et al., 2012).  
 
It was further proposed that this “PARP trapping activity” may have a greater 
contribution to the anti-tumor activity than catalytic inhibition of SSB repair (Murai et 
al., 2012). Clinically-relevant PARPis vary quite significantly in their potency (i.e. 
PARP1 enzyme IC50) and degree of PARP trapping, thus offering a surrogate system to 
study the contribution of PARP-DNA complexes to the lethality of tumor cells 
(Hopkins et al., 2015; Murai et al., 2012) (Table 2).  
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Table 2. Clinically-relevant PARPis vary in PARP trapping activity. Data compiled 
from (Hopkins et al., 2015). 
 
PARPi: Veliparib Olaparib Niraparib Talazoparib 
PARP1 enzyme activity IC50 (nM) 
  
 
3.0±0.2 0.42±0.02 5.0±1.0 0.6±0.18 
PARP Trapping EC50 (nM) 
 
 
19±7 5.0±1.2 14±4 2.7±.0.6 
Fold change in viability  
(BRCA2 WT IC50/BRCA2 MUT 
IC50) 
~143 ~250 
 
~20 ~560 
 
 
These PARP-DNA complexes threaten replication fork integrity and ultimately lead to 
DNA damage, which is especially lethal to HRD cells (Konstantinopoulos et al., 2015) 
(Figure 9C). In support of PARP trapping underlying PARPi cytotoxicity, tolerability of 
various PARPi, as well as synergy with concurrent temozolomide (TMZ) treatment was 
inversely correlated with PARP trapping activity (i.e. Talazoparib/BMN673 (Table 2) 
was least tolerated and showed the greatest synergy with TMZ) (Hopkins et al., 2015). 
BRCA2-specific lethality also seems to correlate with degree of PARP trapping (Table 
2), in support of PARP-DNA lesions being especially toxic in HRD cells. PARPi (at 
doses less than those required for complete inhibition of catalytic function) was also 
shown to sensitize to topoisomerase I poisons topotecan and camptothecin in a 
mechanism that requires PARP1 and implicates PARP trapping and subsequent DNA 
damage as the culprit (Patel et al., 2012). Importantly, genetic loss of PARP1 did not 
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sensitize cells to topoisomerase I poisons, supporting the critical function of PARP 
trapping in potentiating sensitivity to DNA damaging agents. 
 
This model fails to explain, however, why BRCA1/2-deficient cells in particular are 
uniquely sensitive to PARP1 depletion by genetic means (De Lorenzo et al., 2013). 
Future studies should also explore why PARP trapping is specifically lethal in the setting 
of deficient HR and whether other DNA repair alterations may also render cells sensitive 
to this PARPi action. 
 
iv. PARPi prevents PAR-dependent recruitment of BRCA1/BARD1 
BRCA1 rapidly forms nuclear foci following S-phase-associated DNA damage, 
suggesting that it is actively recruited to these sites (Scully et al., 1997). It also co-
localizes with its binding partner, BRCA1 associated ring domain 1 (BARD1) at these 
damage foci.  Recently it was demonstrated that BARD1 recruits BRCA1 to DSBs 
through its phospho-serine binding BRCT motifs in a PARylation-dependent fashion (Li 
& Yu, 2013). In fact, BARD1 binds PAR polymers in vitro and this PARylation at 
BARD1’s C-terminal BRCT motifs is essential for BRCA1 damage-associated foci 
formation. 
 
In response to DNA damage, PARP1 is activated and promptly catalyzes the formation of 
PAR polymers, which are thought to serve as docking sites for a number of repair factors 
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(Langelier & Pascal, 2013). It has thus been hypothesized that PARPi may specifically 
kill BRCA1 mutant cells by preventing BARD1 PARylation and subsequent BRCA1 
recruitment and repair (Figure 9D). While this mechanism seems plausible for a subset 
of hypomorphic BRCA1 mutations – residual tumor BRCA1 function would be ablated 
by PARPi treatment leading to a complete loss of HR – this model is limited to this 
context and fails to explain the synthetic lethality of PARPi and other alterations that 
compromise HR. 
 
v. PARPi inhibits PARP1/PolQ-mediated Alt-EJ 
HR and NHEJ are the two major pathways for the repair of DSBs. Generally, HR is 
restricted to S- and G2-phase of the cell cycle, when there is a preferred repair template 
available to the cell, while NHEJ mostly operates in G1 cells. Recent studies, however, 
shed light on the contribution of alternative end joining (alt-EJ) to S-phase DSB repair, 
especially in BRCA1/2-deficient cells. Specifically, PARP1 and the translesion DNA 
polymerase POLϴ (encoded by POLQ) catalyze alt-EJ as a compensatory DSB pathway 
essential for BRCA1/2-deficient cancer cell viability (Ceccaldi, Liu, et al., 2015; Mateos-
Gomez et al., 2015). Ovarian cancers with mutant BRCA1/2 overexpress POLQ in order 
to prevent the toxic build-up of RAD51-DNA intermediates, thus inhibiting futile HR 
events, while promoting alt-EJ to allow for replication-associated repair compatible with 
cell viability (Ceccaldi, Liu, et al., 2015). Like inhibition of PARP1, which also has a 
critical role in alt-EJ, genetic loss of POLQ is synthetically lethal with HR deficiency in 
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cancer cells. Moreover, cross-breeding of POLQ (alt-EJ deficient) and FANCD2 (HR 
deficient) mutant mice demonstrated embryonic lethality in double knock out (POLQ-/-, 
FANCD2-/-) mice (Ceccaldi, Liu, et al., 2015). While mice with knockout of either gene 
individually have a very mild phenotype, the severity of the double knockout suggests 
that HR and alt-EJ serve in parallel repair pathways that can compensate for loss of the 
other’s activity. 
 
Synthetic lethality between PARP1/POLQ-mediated alt-EJ and HR is an appealing model 
(Figure 9E). Replication-dependent repair of DSBs is a critical and limiting factor for the 
survival of cancer cells. Alt-EJ activity seems to buffer the loss of HR in cancer cells. A 
few key components of this hypothesis remain unaddressed, however. Specifically, if the 
PARPi/HR synthetic lethality is driven by compensatory PARP1-catalyzed alt-EJ, one 
should expect that depletion of other factors that function exclusively in alt-EJ repair 
would similarly compromise HRD cell lethality. Studies that evaluate genetic or 
pharmacological inhibition of enzymes like DNA ligase III (which functions more 
exclusively in alt-EJ) in the setting of HRD would add further clarity to this model. 
Identification of other proteins involved in alt-EJ will also help aid in the elucidation of 
this relationship. Finally, this model might suggest that PARP1 and POLϴ are epistatic in 
cooperating DNA repair of HRD cells. To this end, POLϴ depletion enhances the PARPi 
sensitivity of HRD cells, supporting a contribution of other PARPi activities to synthetic 
lethality in this context. Knockdown of PARP1 by genetic means might help to explain 
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this phenomenon. For instance, if PARP trapping were contributing in concert with loss 
of alt-EJ, PARP1 depletion would not be expected to affect POLQ/HR-deficient cell 
viability. A careful model of PARPi/HR synthetic lethality that considers replication fork 
integrity as a central feature of this relationship may best reconcile these models. 
 
vi. PARPi destabilizes the replication fork 
Loss of BRCA1/2-RAD51-mediated replication fork protection leads to increased 
replication stress and accompanying genomic stability, (i.e. increased replication stress-
induced gross chromosomal aberrations). Among the versatile biological functions of 
PARP1 is its similarly critical role in protecting replication fork integrity. In response to 
replication stalling, PARP1 is activated and facilitates MRE11-dependent resection, 
leading to HR-mediated fork restart (Bryant et al., 2009). In the absence of HR, there is 
increased MRE11 activity, perhaps indicated excessive nucleolytic processing. In fact, 
BRCA1/2 and PARP1 seem to prevent excessive nucleolytic degradation of stalled 
replication forks by parallel mechanisms (Ying et al., 2012) (Figure 9F). This may 
explain the increased activity of PARP1 in the absence of BRCA2 (or alternatively, the 
increase of RAD51 foci in PARP-deficient cells) (Schultz, 2003). Replication fork 
integrity has recently evolved as a central mechanism for maintaining genomic stability 
in BRCA-deficient cells and alterations that restore replication fork protection are likely 
to confer resistance to PARPi (Figure 10).  
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In fact, PARPi-resistant/BRCA2-deficient cells exhibited reduced MRE11 activity, 
consistent with decreased replication fork degradation (Ying et al., 2012). Thus, PARP1’s 
role in limiting replication stress may be critical in understanding BRCA/PARPi 
synthetic lethality. In order to evaluate this model, Schlacher et al. (2011), used a BRCA2 
separation-of-function mutant and demonstrated that the fork protective role of BRCA2 
may be independent of its role in DSB repair and thus, does not confer comparable 
sensitivity to PARPi as mutants that compromise BRCA2 function in HR. Their analysis, 
however, is limited to one mutant, which may not accurately recapitulate the replication 
fork instability conferred by loss of BRCA2 function in tumors. In light of recent 
evidence from our lab and others, it seems that replication fork integrity is in fact a 
critical determinant of PARPi-induced lethality in BRCA1/2-deficient cells. Mechanisms 
that are able to restore replication fork stability in BRCA-mutated cells promote PARPi 
resistance, thus highlighting the importance of this pathway in the underlying synthetic 
lethality between BRCA1/2 and PARP1(Chaudhuri, Callen, Wong, & Nussenzweig, 
2015; Z. Kais, personal communication). Importantly, fork protection is not a function of 
all HR proteins – RAD54 (a RAD51 paralog)-knockout cells did not show apparent 
defects in replication fork protection after HU-induced stalling (Schlacher et al., 2011). It 
would be informative to assess the PARPi sensitivity of these cells (or similar HRD cells 
without replication fork instability) in order to shed light on the contribution of defective 
HR versus defective fork protection to PARPi action. 
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Summary of PARPi mechanism of action 
The versatility of PARP1’s cellular functions make it challenging to determine the 
precise mechanism by which BRCA1/2-deficient cells are exquisitely sensitive to its 
inhibition, yet the models proposed for this synthetic lethality are largely compatible and 
all contribute to explaining some of the unique biological phenomena observed in 
PARPi-treated HRD cells. De Lorenzo and colleagues invoke the parable of the elephant 
and the blind men in their review detailing mechanisms of PARPi/HR synthetic lethality: 
“Like the blind men in the parable, perhaps we can better understand the true nature of 
the elephant by merging several incomplete pictures” (De Lorenzo et al., 2013). 
 
Merging these models paints a more complete picture that may help understand the 
source of PARPi-induced DNA damage, and the BRCA1/2-deficient-specific inadequacy 
in repairing these lesions. In normal cells, BRCA1/2-RAD51 (“HR” for simplicity), in 
conjunction with PARP1, protect stalled replication forks from being degraded and 
promote replication restart. SSBs and DSBs that arise spontaneously in replicating cells 
are repaired by PARP1-mediated BER and HR, respectively, thus preserving genomic 
integrity (Figure 10A). In BRCA1/2-deficient cells, where HR is compromised, PARP1 
activity is elevated in order to promote replication fork stability under conditions of 
increased replicative stress. DSBs in these cells are repaired by error-prone pathways like 
alt-EJ and NHEJ, whose activity is increased to compensate for HR loss (Figure 10B). In 
PARPi-treated BRCA1/2-mutant cells, these compensatory pathways in fork preservation 
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and DSB repair are inhibited, leading to excessive genomic instability driven by 
replication fork collapse and inadequate repair, incompatible with cellular survival 
(Figure 10C). The formation of PARP-DNA complexes through the “PARP trapping” 
mechanism may further burden cells with increased replication stress and DNA damage.  
 
Further elucidating the precise mechanism by which PARPis demonstrate specific 
lethality in BRCA1/2 mutant cells will be critical to determine the tumor-associated 
alterations that may predict clinical response to PARPi and will inform strategies for the 
treatment of tumors that become resistant to PARPi therapy.   
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Figure 10. Revised model for BRCA1/2-PARPi synthetic lethality. BRCA1/2 and 
PARP1 cooperate in several critical processes that maintain genomic stability. Thus 
synthetic lethality is elicited when PARP1 is inhibited. A) BRCA1/2/PARP1 protection 
of stalled replication forks, BRCA1/2-mediated HR, and PARP1-dependent BER all 
contribute to preserve genomic stability. B) Upon loss of BRCA1/2, PARP1 is 
hyperactive to promote replication fork stability and regulate DSB repair (i.e. by 
participating in alt-EJ and inhibiting toxic NHEJ). Shift toward error-prone repair 
processes increase genomic stability and lead to tumorigenesis. C) When BRCA1/2-
deficient cancers are treated with PARPi, tumor cells are unable to tolerate excessive 
genomic instability, leading to cell death. Figure adapted from (Konstantinopoulos et al., 
2015; Ying et al., 2012). 
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DISCUSSION AND FUTURE DIRECTIONS 
 
1. Synthetic lethal model can predict routes to PARPi resistance 
In light of olaparib’s approval for BRCA-mutated EOC in 2014 and the advanced stage 
of clinical investigation of next generation PARPis (Table 1), there is an important need 
to identify the precise mechanism that PARPi is lethal to cancer cells in the context of 
tumor-specific genetic alterations. By using the BRCA1/2-PARP1 synthetic lethal 
interaction as a model system, we will be able to best and then identify molecular 
determinants that predict clinical response to PARPi in ovarian cancer and other 
malignancies, and envisage mechanisms employed by tumor cells in acquiring resistance 
to PARPi. The study at a basic science level, then, requires understanding which 
BRCA1/2 functions compromised in EOC make these tumors susceptible to inhibition of 
PARP1. This will facilitate the identification of genes cooperating in the same pathway 
that may similarly constitute synthetic lethal relationships when they are lost in 
combination with PARPi therapy.  
 
For instance, if compromised HR repair upon BRCA1/2 mutation underlies PARPi 
sensitivity, loss-of-function mutations in other genes in HR may also be synthetic lethal. 
Consistent with this hypothesis, deficiency of FA/BRCA genes FANCA, FANCC, 
FANCD2, RAD51, RAD54, and RPA1, as well as DNA damage response (DDR)/HR 
genes ATR, CHK1, CHK2, was found to confer PARPi sensitivity in a preclincal study 
(McCabe et al., 2006). One strategy to exploit this putative synthetic lethal is to take 
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advantage of the fact that many of these genes are mutated in EOC ((Cancer Genome 
Atlas Research Network, 2011)(Figure 7). Retrospective analysis of PARPi trials could 
resolve whether these mutations are enriched in the non-BRCA mutated PARPi 
responders, thus validating the stratification of these patients for PARPi therapy. 
Moreover, this provides a rationale for combining inhibitors of checkpoint kinases (i.e. 
ATR/ATM/CHK1/2) with PARPis (Anderson et al., 2011; Huntoon et al., 2013; 
Konstantinopoulos et al., 2015). These inhibitors could potentiate PARPi cytotoxicity in 
non-BRCA-mutated tumors. Notably, many of these genes are also involved in 
replication fork stability, thus PARPi response could also be owed to compromised 
replication fork integrity when these proteins are inhibited.  
 
Alternatively, overexpression of genes that inhibit HR activity and promote alternative 
DSB repair pathways (i.e. NHEJ) may also confer sensitivity to conventional 
chemotherapy or PARPis (O’Connor et al., 2013; Pitroda et al., 2014). Cancer cells with 
low “recombination proficiency score (RPS),” as calculated by high expression of four 
genes known to antagonize HR when overexpressed – RIF1, PARI, KU70, and RAD51 - 
demonstrated HR suppression and accompanying sensitivity to DNA damaging agents 
(Pitroda et al., 2014). Moreover, low RPS scores predicted which patients were most 
likely to benefit from adjuvant chemotherapy in breast and non-small cell lung 
carcinoma. Further evaluation of this gene expression score using genomic data for EOC 
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patients on PARPi trials could further validate the utility of using this metric to predict 
clinical outcomes. 
 
Recently, mutations in cohesin genes were identified in a number of solid and blood-
borne cancers (Cancer Genome Atlas Research Network, 2013, 2014)(Figure 11A). 
Cohesin is a multiprotein complex that tethers sister chromatids upon DNA replication 
until their proper segregation to daughter cells in anaphase. The cohesin complex has also 
been credited a role in the DDR, HR, and replication fork progression (Potts, Porteus, & 
Yu, 2006; Terret, Sherwood, Rahman, Qin, & Jallepalli, 2009; Watrin & Peters, 2009). 
Notably, while rare in HGSOC (<3%), mutations in cohesin are mutually exclusive from 
mutations in BRCA1/2 (Figure 11B). Consistent with these functions in genomic 
stability, a recent study proposed that depletion of cohesin genes may confer PARPi 
sensitivity (Bajrami et al., 2014). We have extended these findings to evaluate the 
functionality of cohesin mutations in acute myelogenous leukemia (AML) and find 
results compatible with studies in other models (Bailey et al., 2014; McLellan et al., 
2012; Yadav et al., 2013, A. Holmes and K.W. O'Connor, unpublished observation).  
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Figure 11. Cohesin mutations in EOC and other cancers. A) Cross-cancer incidence 
of cohesin mutations (SMC1A, SMC3, STAG2, and RAD21) is shown. B) Cohesin 
mutations are mutually exclusive from BRCA1/2 mutations in HGSOC. Data generated 
using cBioPortal for patients from the ovarian cancer TCGA study (T. C. G. A. R. 
Network, 2011). 
 
An appealing hypothesis is that sister chromatid cohesion comprises yet another 
mechanism that serves to protect stalled replication forks from collapse. In line with this 
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theory, three cohesin proteins were among 30 proteins identified (by isolation of proteins 
on nascent DNA (iPOND)-mass spectrometry (MS)) to be enriched at replication forks 
after stalling with HU (Lossaint et al., 2013). Moreover, hypomorphic cohesin gene 
mutations are synthetically lethal with other genes implicated in replication fork 
protection (including the C. elegans PARP1 orthologue) (McLellan et al., 2012). Thus, 
cohesin mutations represent another putative biomarker for PARPi sensitivity and an 
attractive model system for delineating the respective contributions of HR-deficiency and 
replication fork instability to PARPi lethality. 
 
Elucidation of mechanisms by which BRCA1/2-deficient tumors become resistant to 
PARPi treatment may also inform which critical functions of BRCA1/2 or PARP1 elicit 
synthetic lethality between the respective pathways. These mechanisms will aid in the 
development of more potent PARPis and investigation of therapeutic avenues for 
targeting resistant tumors. Several recent findings shed light on these critical questions. 
 
Under selective pressure from PARPi (or platinum) treatment, BRCA1/2-mutated tumors 
often become resistant by acquiring secondary intragenic mutations in BRCA1/2 (mostly 
BRCA2) that restore the open reading frame, resulting in a functional gene product and 
thus, restore HR (Edwards et al., 2008; Norquist et al., 2011; W. Sakai et al., 2009; Sakai 
et al., 2008). This finding certainly confirms that BRCA2-deficiency is the underlying 
cause of PARPi response in these patients. What is left unresolved, however, is which 
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function of BRCA2 is critical for PARPi resistance (i.e. DSB repair by HR or replication 
fork stability). In principle, tumors that reactivate BRCA2 should have improved HR and 
replication fork stability. An alternative mechanism was identified by which HR can be 
recovered in the setting of BRCA1 deficiency. Specifically, loss of 53BP1, which 
antagonizes BRCA1-mediated end resection (and subsequent repair by HR) can rescue 
HR, PARPi hypersensitivity, and genomic stability of BRCA1 mutant cells (Bunting et 
al., 2010). This supports the notion that there is a delicate balance between HR and 
NHEJ. When HR is deficient, NHEJ is hyperactive, contributing to genomic instability 
observed in these cells. Importantly, by shifting the balance to restore HR capacity, HRD 
cells can become resistant to PARPi. Whether 53BP1 loss is a physiologically relevant 
mechanism of PARPi resistance in BRCA1-mutant cells has yet to be determined.  
 
More recent preclinical evidence supports the notion that these tumors may also become 
PARPi resistant by alterations that protect replication fork integrity, independent of HR 
restoration. Ying and colleagues suggested that MRE11-dependent degradation of stalled 
replication forks may be associated with PARPi resistance in BRCA2-deficient cells and 
in fact observed this phenomenon in cultured BRCA2-deficient cells that had acquired 
PARPi resistance (Ying et al., 2012). More recently, loss of Pax interacting protein 1 
(PTIP) was shown to rescue replicative stress and fork degradation observed in 
BRCA1/2-deficient cells, by limiting MRE11 localization to stalled replication forks 
(Chaudhuri et al., 2015). Moreover, PTIP loss restores sensitivity to platinum and PARPi 
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and decreased PTIP expression is associated with inferior prognosis in BRCA1/2-mutated 
HGSOCs; thus suggesting that fork stability is a critical mediator of resistance to 
platinum and PARPi. We have similarly shown that overexpression of FANCD2 is able 
to confer PARP resistance in BRCA1/2-deficient ovarian cancer cells by protecting 
replication fork integrity (Z. Kais, personal communication). Additionally, FANCD2 was 
shown to recruit the nuclease FAN1 to sites of stalled replication forks, thereby 
promoting fork restart once DNA repair is completed and preventing fork collapse and 
genomic instability (Lachaud et al., 2016). 
 
Finally, an shRNA screen in BRCA2-deficient (PEO-1) cells revealed that loss of the 
chromatin remodeler, chromodomain helicase DNA binding protein 4 (CHD4) confers 
cisplatin and PARPi resistance by improving efficiency of the damage tolerance 
mechanism translesion synthesis (TLS) ((Guillemette et al., 2015). Convincingly, 
resistant BRCA2-deficient cells without genetic reversion of BRCA2 demonstrated loss 
of CHD4 expression and this event also appears to be relevant to EOC tumor resistance 
and patient outcomes. Notably, TLS is known to compensate for HR in the restart of 
stalled replication forks (Zeman & Cimprich, 2013), suggesting that this may represent 
yet another mechanism of resistance that reinforces replication fork stability. 
 
DNA damage-induced formation of nuclear RAD51 foci serves as a useful surrogate for 
the efficiency of HR repair, yet technical challenges have precluded its utility as a 
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functional biomarker in clinical practice. Alternative approaches using patient genomic 
data have taken advantage of more global signatures of HRD to assess tumor HR 
efficiency (Konstantinopoulos et al., 2015). In deference to the versatile mechanisms by 
which tumors may become resistant to PARPi or platinum-based chemotherapy, 
however, it is fundamental to devise more flexible tools to predict clinical response to 
these agents. Considering the evolving role that replication fork integrity appears to 
occupy in cellular resistance to PARPis, approaches that evaluate replication fork 
stability in patient samples would aid tremendously in clinical decision-making for EOC 
patients. Two in vitro assays – DNA combing/fiber analysis, and iPOND – have been 
developed to evaluate replication fork dynamics with single molecule resolution and to 
identify putative factors involved in replication fork stability (Bensimon et al., 1994; 
Sirbu et al., 2013). Like RAD51 foci, however, these tools are technically cumbersome 
and will be difficult to translate to assays that are compatible with patient samples.  
 
 2. Concluding remarks about targeted therapy in EOC 
The success of PARPis in treating ovarian cancer patients with BRCA1/2-deficient 
tumors represents a proof-of-concept for the application of synthetic lethality toward 
cancer therapeutics. While this work has pointed out some of the limitations of PARPi 
therapy, its use in EOC is clearly justified by its favorable safety profile and ability to 
improve quality of life for a large subset of patients. Some of the major challenges that 
remain are addressing the precise population of patients that may benefit from PARPi, 
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strategies to combat resistance, and ways to increase the potency of PARPi in order to 
improve its clinical efficacy.  
 
From a basic science perspective, many of the answers to these questions may lie in 
understanding how PARPis elicit synthetic lethality in BRCA1/2-deficient cells on a 
molecular level. Forward thinking researchers and clinicians have collaborated 
successfully in this regard – ten years after the discovery of this robust genetic 
relationship, the first PARPi olaparib was approved by the FDA. In the interim, countless 
scientists have sought to define more precisely the molecular underpinnings of this 
relationship. Their findings are poised to help improve PARPi treatment and ultimately, 
more fully exploit the “fundamental vulnerabilities” in EOC and in other human 
malignancies.      
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APPENDIX I 
Inherited inactivation of the FA/BRCA pathway: Fanconi anemia  
Children born with mutations in FA genes are affected by the heterogeneous cancer 
susceptibility disorder Fanconi anemia (Ceccaldi, Sarangi, et al., 2016). There have been 
19 subtypes of FA identified to date (i.e. 19 genes identified as pathogenic for FA). These 
genes are termed “FA” or “FANC-” genes (Ceccaldi, Sarangi, et al., 2016). Clinical 
hallmarks of FA include skeletal abnormalities, skin hyper- or hypo-pigmentation, 
aplastic anemia, and early onset of both myeloid and squamous cell malignancies 
(Moldovan & D’Andrea, 2009). Cells from FA patients are remarkably sensitive to ICL-
inducing agents, such as mitomycin-C (MMC), diepoxybutane (DEB), cisplatin, and 
endogenous alcohol metabolites (Langevin, Crossan, Rosado, Arends, & Patel, 2011). A 
striking and clinically diagnostic manifestation of the underlying DNA repair deficiency 
in FA cells is the formation of radial chromosomes following exposure to these agents 
(Auerbach, 1988; Moldovan & D’Andrea, 2009). Many of these cellular phenotypes are 
shared by cells deficient in breast cancer susceptibility genes BRCA1 and BRCA2, 
provoking speculation of an interrelated role between the FA and “BRCA” pathways. 
This notion was later supported by co-localization and interaction studies (Garcia-
Higuera et al., 2001) and the subsequent discovery of a homozygous germline BRCA2 
mutation in a patient with FA (FA subtype D-1) cemented a link between these hereditary 
breast and ovarian cancer (Howlett et al., 2002). Ensuing research on the FA/BRCA 
pathway using murine models and immortalized human cell lines from FA patients has 
revealed the precise molecular mechanism by which these proteins coordinate ICL repair. 
Clinically, loss-of-function mutations in FA or BRCA genes render tumors sensitive to 
platinum agents. 
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Chromosome radials. Radial form chromosomes are characteristic of both FA cells (left, 
FA subtype D1 (BRCA2-/-) and cancer cells with somatic inactivation of FA/BRCA 
genes (right, CAPAN-1, pancreatic adenocarcinoma cell line). Representative metaphase 
spreads are shown. Red arrows indicate radial chromosomes. Figure taken from (“Color 
Figures,” 2002). 
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APPENDIX II 
 
Rationale and status of PARPi combination trials. Figure taken from 
(Konstantinopoulos et al., 2015) 
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